Description
SC Administration
– For SC injection at separate sites in the thigh or lower abdomen (avoiding areas within 2 inches of navel)
– Rotate injection sites
– May leave at room temperature for ~15 to 30 minutes prior to use; do not remove cap or cover while allowing product to reach room temperature
– Do not use if solution is discolored or contains particulate matter
– Do not administer to skin which is red, tender, bruised, hard, or that has scars, stretch marks, or psoriasis plaques
– Needle cap of the prefilled syringe or needle cover for the adalimumab pen may contain latex
– Prefilled pens and syringes are available for use by patients and the full amount of the syringe should be injected (self-administration); the vial is intended for institutional use only
– Vials do not contain a preservative; discard unused portion
Storage
– Store at 2°C to 8°C (36°F to 46°F) in original container to protect from light
– Do not freeze
– Do not use if frozen even if it has been thawed
– Do not store in extreme heat or cold
– If needed, may be stored at room temperature up to a maximum of 25°C (77°F) for up to 14 days; discard if not used within 14 days
Monitoring
– Monitor improvement of symptoms and physical function assessments
– Latent TB screening prior to initiating and during therapy
– Signs/symptoms of active infection, including tuberculosis (prior to, during, and following therapy)
– CBC with differential
– Signs/symptoms/worsening of heart failure
– HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy)
– Signs and symptoms of hypersensitivity reaction
– Symptoms of lupus-like syndrome
– Signs/symptoms of malignancy (splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss), including periodic skin examination
